BIOMAT Database Logo BIOMAT Database Logo

Prognostic factors in node positive primary breast cancer patients treated with adjuvant CMF. 1992

E Campora, and P Pronzato, and D Amoroso, and G F Bertelli, and M Venturini, and E Baldini, and I Brunetti, and M R Sertoli, and P Conte, and R Rosso
Department of Medical Oncology, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy.

The influence of various patient and disease-related parameters on survival (S) and disease-free survival (DFS) in 217 node positive primary breast cancer patients treated with surgery followed by adjuvant i.v. cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) was evaluated by univariate and multivariate analyses. Five year actuarial S and DFS were 73.3% and 54.8%, respectively. Univariate analysis revealed that patient age, number of involved axillary nodes and ER status had a significant impact on both S and DFS. PgR positive tumors had improved DFS but no S difference was observed. Menopausal status predicted S but not DFS. Primary tumor size and CMF-induced amenorrhea did not predict disease outcome. Multivariate analysis demonstrated that only degree of nodal involvement and PgR status had independent significant impact on prognosis. Both S and DFS are significantly influenced by the number of involved nodes, whereas improved DFS but not S was evident in patients with PgR positive tumors.

UI MeSH Term Description Entries
D008207 Lymphatic Metastasis Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system. Lymph Node Metastasis,Lymph Node Metastases,Lymphatic Metastases,Metastasis, Lymph Node
D008727 Methotrexate An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. Amethopterin,Methotrexate Hydrate,Methotrexate Sodium,Methotrexate, (D)-Isomer,Methotrexate, (DL)-Isomer,Methotrexate, Dicesium Salt,Methotrexate, Disodium Salt,Methotrexate, Sodium Salt,Mexate,Dicesium Salt Methotrexate,Hydrate, Methotrexate,Sodium, Methotrexate
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011960 Receptors, Estrogen Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important. Estrogen Receptor,Estrogen Receptors,Estrogen Nuclear Receptor,Estrogen Receptor Type I,Estrogen Receptor Type II,Estrogen Receptors Type I,Estrogen Receptors Type II,Receptor, Estrogen Nuclear,Receptors, Estrogen, Type I,Receptors, Estrogen, Type II,Nuclear Receptor, Estrogen,Receptor, Estrogen
D011980 Receptors, Progesterone Specific proteins found in or on cells of progesterone target tissues that specifically combine with progesterone. The cytosol progesterone-receptor complex then associates with the nucleic acids to initiate protein synthesis. There are two kinds of progesterone receptors, A and B. Both are induced by estrogen and have short half-lives. Progesterone Receptors,Progestin Receptor,Progestin Receptors,Receptor, Progesterone,Receptors, Progestin,Progesterone Receptor,Receptor, Progestin
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D005260 Female Females
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU

Related Publications

E Campora, and P Pronzato, and D Amoroso, and G F Bertelli, and M Venturini, and E Baldini, and I Brunetti, and M R Sertoli, and P Conte, and R Rosso
Adjuvant chemotherapy with CEF versus CMF for node-positive breast cancer.
December 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
E Campora, and P Pronzato, and D Amoroso, and G F Bertelli, and M Venturini, and E Baldini, and I Brunetti, and M R Sertoli, and P Conte, and R Rosso
Intravenous or oral adjuvant CMF for node-positive breast cancer.
July 1992, The Australian and New Zealand journal of surgery,
E Campora, and P Pronzato, and D Amoroso, and G F Bertelli, and M Venturini, and E Baldini, and I Brunetti, and M R Sertoli, and P Conte, and R Rosso
Prognostic factors in node-positive operable breast cancer patients receiving adjuvant chemotherapy.
January 1992, Breast cancer research and treatment,
E Campora, and P Pronzato, and D Amoroso, and G F Bertelli, and M Venturini, and E Baldini, and I Brunetti, and M R Sertoli, and P Conte, and R Rosso
Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF.
August 1999, British journal of cancer,
E Campora, and P Pronzato, and D Amoroso, and G F Bertelli, and M Venturini, and E Baldini, and I Brunetti, and M R Sertoli, and P Conte, and R Rosso
Quality of adjuvant CMF chemotherapy for node-positive primary breast cancer: a population-based study.
October 2004, Journal of cancer research and clinical oncology,
E Campora, and P Pronzato, and D Amoroso, and G F Bertelli, and M Venturini, and E Baldini, and I Brunetti, and M R Sertoli, and P Conte, and R Rosso
BCIRG 001 molecular analysis: prognostic factors in node-positive breast cancer patients receiving adjuvant chemotherapy.
August 2010, Clinical cancer research : an official journal of the American Association for Cancer Research,
E Campora, and P Pronzato, and D Amoroso, and G F Bertelli, and M Venturini, and E Baldini, and I Brunetti, and M R Sertoli, and P Conte, and R Rosso
CD44/CD24 as potential prognostic markers in node-positive invasive ductal breast cancer patients treated with adjuvant chemotherapy.
February 2014, Journal of molecular histology,
E Campora, and P Pronzato, and D Amoroso, and G F Bertelli, and M Venturini, and E Baldini, and I Brunetti, and M R Sertoli, and P Conte, and R Rosso
Dose intensity of standard adjuvant CMF with granulocyte colony-stimulating factor for premenopausal patients with node-positive breast cancer.
January 1996, Oncology,
E Campora, and P Pronzato, and D Amoroso, and G F Bertelli, and M Venturini, and E Baldini, and I Brunetti, and M R Sertoli, and P Conte, and R Rosso
Predictive factors for omitting lymphadenectomy in patients with node-positive breast cancer treated with neo-adjuvant systemic therapy.
May 2020, The breast journal,
E Campora, and P Pronzato, and D Amoroso, and G F Bertelli, and M Venturini, and E Baldini, and I Brunetti, and M R Sertoli, and P Conte, and R Rosso
Adjuvant CMF for node-negative and estrogen receptor-negative breast cancer patients.
January 1992, Journal of the National Cancer Institute. Monographs,
Copied contents to your clipboard!